ANAEMIA and Ambien

PatientsVille

Find and Compare Side Effects

ANAEMIA Symptoms and Causes

If you have anemia, your blood does not carry enough oxygen to the rest of your body. The most common cause of anemia is not having enough iron. Your body needs iron to make hemoglobin. Hemoglobin is an iron-rich protein that gives the red color to blood. It carries oxygen from the lungs to the rest of the body.

Anemia has three main causes: blood loss, lack of red blood cell production, and high rates of red blood cell destruction.

Conditions that may lead to anemia include

Heavy periods

Pregnancy

Ulcers

Colon polyps or colon cancer

Inherited disorders

A diet that does not have enough iron, folic acid or vitamin B12

Blood disorders such as sickle cell anemia and thalassemia, or cancer

Aplastic anemia, a condition that can be inherited or acquired

G6PD deficiency, a metabolic disorder

Anemia can make you feel tired, cold, dizzy, and irritable. You may be short of breath or have a headache.

Your doctor will diagnose anemia with a physical exam and blood tests. Treatment depends on the kind of anemia you have.

ANAEMIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

The portion of drug responders as defined by changes in the platelet count and/or platelet transfusion requirements or hemoglobin and/or PRBC transfusion requirements and the toxicity profile as measured using the CTCAE criteria.; Incidence of bleeding, changes in serum thrombopoietin level, and health related quality of life (as measured by the Medical Outcomes Study 36-Item Short Form General Health Survey, version 2 [SF36v2] Quality-Metric) measured at 16 weeks.

To determine if the use of intravenous ferric carboxymaltose can reduce the need for allogeneic blood transfusion compare to oral ferrous sulphate in patients with colorectal adenocarcinoma related Anaemia; To determine differences in hemoglobin and hematinic markers between the groups.; To determine differences in hepcidin levels in relation to blood profile changes in participants in the intravenous group.; To determine differences in colonic mucosal expression of iron transport proteins, C-myc and NKD1 between the groups; To determine differences in postoperative outcomes between the groups.; To determine differences in anemia symptomatology response between groups.

To develop Teff bread that is rich in iron (per slice).; To establish whether iron from Teff is bioavailable.; To conclude whether daily Teff consumption prevents iron-deficiency anemia in pregnancy.; To use a range of different biomarkers to determine iron status.; To compare dietary intakes of iron and iron status between the Teff/control group.

Measure the ability to administer twice daily oral quercetin therapy in patients with Fanconi Anemia (FA).; Measure safety of oral quercetin therapy in patients with FA; To measure pharmacokinetics (PK) of oral quercetin therapy in patients with FA; To measure the impact of quercetin therapy on reduction of Reactive Oxygen Species (ROS).; Number of participants with improved hematopoiesis.; Measure the preservation of hematopoietic stem cell reserve in patients with FA; Number of participants with changes in insulin sensitivity/glucose tolerance.

Response rate at six months, defined as no longer satisfying blood count criteria for SAA.; Relapse, robustness of the hematopoietic recovery at three and six months, three months responses, survival, and clonal evolution to myelodysplasia and acute leukemia.

To test if the proportion of subjects achieving a Hb value >/= 10.0 g/dL at any time point after the first dose during the study is greater than 0.8 when administered de novo darbepoetin alfa QW for treatment of anemia in pediatric CKD subjects receiving; To test if the proportion of subjects achieving a Hb value >/= 10.0 g/dL at any time point after the first dose during the study is greater than 0.8 when administered de novo darbepoetin alfa Q2W for treatment of anemia in pediatric CKD subjects receivin; To assess the health-related quality of life in pediatric CKD subjects >/= 2 years old over the duration of the study in the QW and Q2W arms; To obtain pharmacokinetic (PK) data in subjects < 6 years of age; To assess the safety and tolerability of darbepoetin alfa administered QW and Q2W; To estimate Hb values over the duration of the study in the QW and Q2W arms; To estimate doses over the duration of the study in the QW and Q2W arms

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly.
PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.